Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
13 04 2022
Historique:
received: 13 01 2022
accepted: 24 03 2022
entrez: 14 4 2022
pubmed: 15 4 2022
medline: 16 4 2022
Statut: epublish

Résumé

Israel began administering a BNT162b2 booster dose to restore protection following the waning of the 2-dose vaccine. Biological studies have shown that a "fresh" booster dose leads to increased antibody levels compared to a fresh 2-dose vaccine, which may suggest increased effectiveness. To compare the real-world effectiveness of a fresh (up to 60 days) booster dose with that of a fresh 2-dose vaccine, we took advantage of a quasi-experimental study that compares populations that were eligible to receive the vaccine at different times due to age-dependent policies. Specifically, we compared the confirmed infection rates in adolescents aged 12-14 (215,653 individuals) who received the 2-dose vaccine and in adolescents aged 16-18 (103,454 individuals) who received the booster dose. Our analysis shows that the confirmed infection rate was lower by a factor of 3.7 (95% CI: 2.7 to 5.2) in the booster group.

Identifiants

pubmed: 35418201
doi: 10.1038/s41467-022-29578-w
pii: 10.1038/s41467-022-29578-w
pmc: PMC9008037
doi:

Substances chimiques

BNT162 Vaccine N38TVC63NU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1971

Informations de copyright

© 2022. The Author(s).

Références

N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
Nat Med. 2022 Mar;28(3):477-480
pubmed: 35046572
Nat Med. 2021 Jun;27(6):1055-1061
pubmed: 33875890
N Engl J Med. 2021 Dec 23;385(26):2421-2430
pubmed: 34879188
JAMA. 2021 Dec 7;326(21):2203-2204
pubmed: 34739043
Lancet. 2021 Dec 4;398(10316):2093-2100
pubmed: 34756184
N Engl J Med. 2022 Feb 3;386(5):492-494
pubmed: 34965337
Viruses. 2022 Sep 13;14(9):
pubmed: 36146829
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
Lancet Microbe. 2022 Jan;3(1):e52-e61
pubmed: 34806056
PLoS Comput Biol. 2021 Feb 11;17(2):e1008559
pubmed: 33571188
Clin Infect Dis. 2004 Jun 1;38(11):1586-91
pubmed: 15156447

Auteurs

Ofra Amir (O)

Technion-Israel Institute of Technology, Haifa, Israel.

Yair Goldberg (Y)

Technion-Israel Institute of Technology, Haifa, Israel. yairgo@technion.ac.il.

Micha Mandel (M)

The Hebrew University of Jerusalem, Jerusalem, Israel.

Yinon M Bar-On (YM)

Department of Plant and Environmental Sciences, Weizmann Institute of Science, Rehovot, Israel.

Omri Bodenheimer (O)

Israel Ministry of Health, Jerusalem, Israel.

Nachman Ash (N)

Israel Ministry of Health, Jerusalem, Israel.

Sharon Alroy-Preis (S)

Israel Ministry of Health, Jerusalem, Israel.

Amit Huppert (A)

The Bio-statistical and Bio-mathematical Unit, The Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical Center, Ramat Gan, Israel.
The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Ron Milo (R)

Department of Plant and Environmental Sciences, Weizmann Institute of Science, Rehovot, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH